ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0463

Utilization of a Giant Cell Arteritis Fast-Track Program Independent of Ultrasound at a Single Center

Christina Costeas, Shubhasree Banerjee, Madhura Tamhankar, Naomi Amudala, Peter Merkel and Rennie Rhee, University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2022

Keywords: giant cell arteritis, Health Services Research, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: The Giant Cell Arteritis (GCA) Fast-Track program was implemented at our center with the goal of accelerating diagnosis of this rare and rapidly progressive disease. The main components of the program are outlined in Figure 1. Prior studies have demonstrated that GCA fast-track programs improve outcomes. It is unclear whether expedited, specialized care delivered through a fast-track process improves quality of care and outcomes in GCA independent of temporal artery ultrasound. This study evaluated our GCA fast-track program with the hypothesis that rapid, multi-disciplinary care of patients with suspected GCA enables achievement of goals outlined by clinical management guidelines without the use of temporal artery ultrasound.

Methods: Patients referred to our GCA Fast-Track program between January 2020 and January 2022 were included. Patients were excluded from analysis if they had a previous diagnosis of GCA or incomplete medical records. Process measures included time to rheumatology evaluation, use of glucocorticoids, temporal artery biopsy, and large-vessel screening as per published guidelines. Complications of GCA were defined as permanent vision loss, large-vessel manifestations (aneurysm, stenosis, dissection), or death. Groups were compared using the Wilcox rank-sum test or Fisher’s exact test.

Results: Among 65 patients referred to the program, 57 patients were included in the analysis summarized in Table 1. Nine lower risk patients were determined not to need a rheumatology appointment after initial triaging. Patients who were ultimately diagnosed with GCA were seen more quickly by rheumatology after referral than those who were not diagnosed with GCA (1 day vs. 4 days, p=0.03). 47% of patients underwent temporal artery biopsy (TAB) with the overall TAB positivity rate being 26%. Most patients seen through this program met the standards outlined in the American College of Rheumatology guidelines. All patients diagnosed with GCA that experienced visual symptoms were seen by an ophthalmologist. None of the patients diagnosed with GCA through the fast-track experienced permanent vision loss or any other disease-related complications. Normal C-reactive protein was observed in 0% of GCA vs 44% of non-GCA groups during evaluation for GCA.

Conclusion: Our Fast-Track program provided high-quality, comprehensive care for patients undergoing evaluation for GCA without relying on temporal artery ultrasound. Effective triaging enabled appropriate use of resources and no patients experienced disease-related complications including permanent blindness during the follow-up period. Future use of normal pre-treatment C-reactive protein to refine the triaging process may also be considered. Although the COVID-19 pandemic impacted the volume of patients and operations at our center, these data are likely generalizable to a non-pandemic situation. Further studies are needed to compare outcomes between conventional and fast-track pathways.

Supporting image 1

Figure 1. Flow diagram of our Giant Cell Arteritis (GCA) Fast-Track Program. Key components of the program include initial triaging, expedited appointments for multiple specialties, and access to vasculitis specialists for GCA evaluation and management.

Supporting image 2

The index date was defined as the first day a provider considered the diagnosis of GCA. Normal C-reactive protein defined as less than 0.8 mg/dL. Values are reported as medians with the interquartile range unless indicated otherwise. GCA, giant cell arteritis; TAB, temporal artery biopsy.


Disclosures: C. Costeas, None; S. Banerjee, None; M. Tamhankar, None; N. Amudala, None; P. Merkel, AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Neutrolis, Takeda, CSL Behring, Dynacure, EMDSerono, Immagene, Jannsen, Kiniksa, Magenta, Novartis, Pfizer, Q32, Regeneron, Sparrow, Eicos, Electra, Kyverna, UpToDate; R. Rhee, ChemoCentryx.

To cite this abstract in AMA style:

Costeas C, Banerjee S, Tamhankar M, Amudala N, Merkel P, Rhee R. Utilization of a Giant Cell Arteritis Fast-Track Program Independent of Ultrasound at a Single Center [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/utilization-of-a-giant-cell-arteritis-fast-track-program-independent-of-ultrasound-at-a-single-center/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utilization-of-a-giant-cell-arteritis-fast-track-program-independent-of-ultrasound-at-a-single-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology